HTN treatment lecture Flashcards
essential (primary) HTN
unknown cause (90%)
secondary HTN
identifiable cause (disease, drug, CKD, NSAIDs) (5-10%)
white coat HTN
BP increases in a clinical setting, normal or low at home
pseudohypertension
BP falsely elevated due to rigid calcified brachial artery
osler’s maneuver
used to test for pseudohypertension.
BP cuff inflated above peak SBP, if radial artery remains palpable + osler’s (pseudohypertension)
isolated systolic HTN
only systolic is high
DBP is normal or low
resistant HTN
not at goal BP but on max dose of at least 3 drugs; one of which includes a diuretic
hypertensive crisis
> 180/120
Emergency if TOD- goal DBP<110 over min-hours with IV agents
urgency if no TOD- can use PO agents to decrease BP to stage 1 values over several hours
diagnosis of HTN is based on
2 reading taken on separate occasions
home readings over 5-7 days greater than ____ are abnormal
> 130/85
ambulatory BP monitoring (ABPM)
checks BP every 15 minutes over 24 hours
- should drop 10-20% during sleep
- > 130/85 abnormal
normal BP
<120/80
prehypertension
SBP 120-139 ot DBP 80-89
Stage 1
SBP 140-159 or DBP 90-99
stage 2
SBP >160 or DBP>100
major cardiovascular risk factors
HTN, obesity, dyslipidemia, DM, smoking, inactivity, albuminuria (GFR55 men, >65 women), family history
identifiable causes of HTN
sleep apnea, drug induced, primary alosteronism, renovascular disease, cushing syndrome, steroids, pheochomacytoma, CKD, thyroid/parathyroid disease, coarctation of aorta
diagnostic work up steps
- assess risk factors & co-morbidities
- reveal identifiable causes
- assess presence of target organ damage
- history & physical exam
5/ baseline lab tests
lifestyle modification
- weight reduction (normal BMI 18.5-24.9)
- Dash diet
- Na restriction (< 2400mg; <1 drink in women
BP goal for most patients
<140/90
BP goal for >80 & 60-80 who are frail
<150/90
BP goal for anyone who has DM or CKD
<140/90
compelling indications
- left ventricular dysfunction
- post MI
- coronary artery disease
- DM
- CKD
- recurrent stroke prevention
stage 1 therapy w/ no compelling indicators
monotherapy using ACEI, ARB, CCB, or thiazide
stage 1 black patients w/ no compelling indicators should be started on
CCB or thiazide
stage 2 therapy w/ no compelling indicators
2 drug combo for most
thiazide or CCB + ACEI or ARB
primary anihypertensives
ACEI, ARBs, thiazides, CCBs
alternative antihypertensives
beta-blockers, direct renin inhibitors, alpha-blockers (peripheral), central alpha2-agonst, adrenergic inhibitors, vasodilators
ALLHAT conclusions
- no difference in primary outcome or all-cause mortality
- ACEI less effective in black patients to decrease BP & CV outcomes (as mono therapy)
- chlorthalidone was the drug of choice bc decreased secondary outcomes & at the same time was least expensive
- more than 1 agent was required to control BP in most patients
diuretics have synergistic effect w/ other agents. esp:
ACEI/ARBs & beta-blockers
diuretic early BP decrease due to
diuresis
diuretic chronic BP decrease due to
decreased PR
1st generation thiazides not effective in
significant renal impairment (SCr >2.5, CrCl <30)
thiazides may be considered 1st line, esp in
blacks & elderly
thiazide most common side effects
hypokalemia, hypo-Mg, hyperuricemia
thiazide clinical pearls
- diuretic decreases w/ time
- takes 2-3 weeks to see max benefit
- chlrthalidone is ~1.5X more potent than HCTZ & has longer T1/2
- increase dose leads to increased electrolyte problems. generally limit HCTZ dose to 25mg/day
thiazide diuretics
HCTZ & chlorthalidone
Thiazide-like diuretics
indapamide & metolazone
loop diuretics
furosemide, torsemide, bumetamide
loop diuretics may be considered in uncomplicated HTN in patients with
significant renal dysfunction not responsive to thiazides
loop diuretic clinical pearls
limited routine use
biggest role is resistant HTN in presence of renal dysfunction
significant diuresis & electrolyte problems
potassium-sparing diuretic clinical pearls
primarily used with thiazides to decrease hypokalemia
may cause hyperkalemia, esp. in combo w/ ACEI/ARB
aldosterone antagonists (K-sparing) drugs
eplerenone & spironolactone
k- sparing drugs (Na channel)
amiloride, trimterene
aldosterone antagonists contraindications
- spironolactone should be avoided in CrCl 1.8 (women), >2(men), & T2DM w. albuminuria
aldosterone antagonist clinical pearls
may cause significant hyperkalemia, esp. w/ ACEI/ARB or K supplements